The filing, via book-runner Oppenheimer and Ladenburg Thalmann, comes with a placeholder size of $35M.
The clinical stage biotech company's looking to list the ADS on Nasdaq under the symbol ANCN.
For the nine months ended Sept. 30, expenses climbed to $10.1M from a prior-year $7.5M; R&D was closer to flat at $5.72M vs. a previous $5.22M. The company reports cash and equivalents of $10.9M as of Sept. 30.
From the filing, other companies working on treatments targeted for non-muscle invasive bladder cancer patients who have failed BCG treatment include Merck Sharp & Dohme; Sesen Bio (NASDAQ:SESN); Telesta Therapeutics (OTCPK:BNHLF); Heat Biologics (NASDAQ:HTBX); Viralytics (OTCQX:VRACY); UroGen Pharma (NASDAQ:URGN); Halozyme (NASDAQ:HALO); Astellas (OTCPK:ALPMY); Cold Genesys; Altor BioScience; FKD Therapies; Nippon Kayaku (OTCPK:NPKYY); Spectrum Pharmaceuticals (NASDAQ:SPPI); Taris Biomedical; and Handok.
Subscribe for full text news in your inbox